BetterLife Pharma (BETR) AI Stock Analysis

• Market Cap: C$10.63M
• Dividend Yield: N/A
• Average Volume (3M): 121.96K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.19
• Revenue Growth: N/A
• EPS Growth: 62.43%
• Country: CA
• Employees: 4
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 151,896,680
• 10 Day Avg. Volume: 118,740
• 30 Day Avg. Volume: 121,961
• PEG Ratio: -0.60
• Price to Book (P/B): -1.51
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.96
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: C$0.09 ▲(115.00% Upside)
• Action: Reiterated Date: 03/07/26
• Date: Action: Reiterated 03/07/26

The score is held back primarily by fragile financials (no revenue, ongoing losses, negative equity), partially offset by improving recent cash burn/loss trends. Technicals are the main positive with clear upward price momentum, while valuation provides limited support due to negative earnings and no dividend.

Positive Factors

Improving cash burn

Operating cash outflow has narrowed materially, indicating the company reduced discretionary spending or optimized operations. This durable reduction extends runway and lowers near-term financing pressure, improving odds of advancing clinical programs over the next several quarters.

Narrowing net losses

Consistent year-over-year reduction in net losses suggests improving operational efficiency and tighter cost control. Over a 2–6 month horizon this trend supports sustainability of R&D activity without proportionate increases in external funding, reducing dilution risk if maintained.

Focused therapeutic strategy

A clear focus on mental health and neurology targets large, structural unmet needs and established regulatory pathways. This concentration helps prioritize R&D spend, attract targeted partnerships or grants, and supports durable strategic positioning versus unfocused early-stage peers.

Negative Factors

No revenue

Absence of product revenue means the business remains fully pre-revenue and dependent on financing for operations. That limits visibility into commercial viability and means sustaining R&D and development timelines requires continued capital access over many quarters.

Negative shareholders' equity

Material negative equity and minimal tangible assets constrain financial flexibility and increase restructuring or dilution risk. Over a multi-quarter horizon, this weak capital structure narrows strategic options and heightens dependence on external funding or partnerships to continue operations.

Ongoing negative free cash flow

Despite improved burn, free cash flow remains negative, signaling persistent funding needs to support R&D and corporate costs. This structural cash shortfall implies recurring financing requirements that can dilute shareholders or delay programs if capital access tightens over the next several quarters.

BetterLife Pharma Business Overview & Revenue Model

Company Description

BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of neurological disorders in Canada and internationally. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's pipeline products include BETR-001 for the treatment of major depressive disorder, treatment resistance depression, cluster headaches, and post-traumatic stress disorder; and BETR-002 to treat benzodiazepine dependency, anxiety, and spasticity. It is also developing MM-003 for treatment of COVID-19 and other respiratory viral infections; MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and AP-002 for the treatment of cancer. BetterLife Pharma Inc. has a research agreement with the University of California San Diego for preclinical behavioral pharmacology studies of TD-0148A, a lysergic acid diethylamide derivative solution. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.

How the Company Makes Money

BetterLife Pharma makes money primarily through the development and commercialization of its therapeutic products. The company's revenue model is based on the successful advancement of its drug candidates through clinical trials and obtaining regulatory approvals, which can lead to partnerships or licensing agreements with larger pharmaceutical companies. Additionally, as these therapies reach the market, BetterLife Pharma could generate revenue through direct sales or royalties from licensing agreements. Investment from venture capital or strategic partners also plays a significant role in funding the company's research and development activities, which indirectly contributes to its financial sustainability.

BetterLife Pharma Financial Statement Overview

Summary

Financial profile remains weak: no revenue, ongoing net losses, and negative free cash flow. While TTM loss and cash burn have improved materially versus prior years, persistent negative shareholders’ equity and a very small asset base increase financing/dilution risk.

Income Statement

The company reports no revenue across the available periods, so losses are the core story. Net losses have narrowed materially versus earlier years (Annual 2021 and 2022 were far larger losses than recent periods), and TTM (Trailing-Twelve-Months) net loss (~$1.9M) is also improved versus Annual 2023–2024. However, profitability remains firmly negative with ongoing operating losses, and the absence of revenue limits visibility into a path toward sustainable earnings.

Balance Sheet

The balance sheet shows persistent negative shareholders’ equity (e.g., about -$9.5M in TTM (Trailing-Twelve-Months) and about -$10.7M in Annual 2025), which is a major financial risk flag and suggests a weak capital position. Total assets are very small (roughly $0.2–$0.3M recently), leaving limited balance-sheet flexibility. Debt is modest in absolute terms (about $0.7M TTM (Trailing-Twelve-Months)), but negative equity makes leverage metrics less meaningful and underscores dependence on external financing.

Cash Flow

Cash burn is still present, but has improved sharply in the most recent period: TTM (Trailing-Twelve-Months) operating cash flow is about -$0.22M versus roughly -$2.0M in Annual 2025 and -$2.5M in Annual 2024. Free cash flow tracks operating cash flow and remains negative, indicating ongoing funding needs. While the reduced burn rate is a positive near-term signal, the company is not yet generating self-sustaining cash flow.

Breakdown	TTM	Apr 2025	Apr 2024	Apr 2023	Apr 2022	Apr 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	-18.43K	-18.44K	―
EBITDA	-1.79M	0.00	-3.19M	-9.24M	-11.92M	-7.61M
Net Income	-1.85M	-3.52M	-2.89M	-9.02M	-12.16M	-36.35M
Balance Sheet
Total Assets	291.13K	224.96K	324.75K	74.73K	1.16M	1.34M
Cash, Cash Equivalents and Short-Term Investments	7.96K	8.18K	37.38K	8.31K	173.51K	154.72K
Total Debt	659.63K	1.30M	1.47M	1.19M	1.40M	500.00K
Total Liabilities	6.46M	7.59M	8.02M	7.61M	5.04M	5.95M
Stockholders Equity	-9.46M	-10.68M	-10.81M	-10.73M	-3.88M	-4.61M
Cash Flow
Free Cash Flow	-217.62K	-2.02M	-2.47M	-1.50M	-11.20M	-7.26M
Operating Cash Flow	-217.61K	-2.02M	-2.47M	-1.50M	-11.20M	-7.16M
Investing Cash Flow	0.00	0.00	0.00	165.04K	-18.77K	-71.55K
Financing Cash Flow	206.94K	1.99M	2.50M	1.34M	11.23M	4.09M

BetterLife Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BETR, the sentiment is Positive. The current price of 0.04 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.06, and below the 200-day MA of 0.07, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 54.83 is Neutral, neither overbought nor oversold. The STOCH value of 41.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BETR.

BetterLife Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BETR	52 Neutral	C$10.63M	-6.03	19.14%	―	―	62.43%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MDMA	49 Neutral	C$10.89M	-6.26	-78.88%	―	-72.51%	-170.13%
MRVL	45 Neutral	C$8.99M	-8.93	64.41%	―	―	―
MOOD	45 Neutral	C$5.61M	-4.13	-41.36%	―	-50.89%	-32.33%
PHRM	42 Neutral	C$6.37M	-10.53	-112.32%	―	―	27.35%

BetterLife Pharma Corporate Events

BetterLife Pharma Grants 6.05 Million Stock Options to Insiders

BetterLife Pharma has granted 6,050,000 stock options to its directors, officers and employees, each exercisable at $0.055 per share over five years and vesting in four equal tranches from the grant date through 18 months. The move underscores the company’s use of equity-based incentives to align management and staff with long-term value creation as it advances BETR-001 through preclinical and IND-enabling studies and evaluates strategic options for its antiviral candidate.

The option grant may help BetterLife retain and motivate key personnel at a critical stage in its development pipeline, where progress on BETR-001 and potential monetization of its antiviral asset could shape future growth. By reinforcing internal incentives while holding a portfolio of patent-backed neurological and antiviral candidates, the company is positioning itself to compete in the emerging market for next-generation neuropsychiatric therapies and related therapeutics.

The most recent analyst rating on (TSE:BETR) stock is a Hold with a C$0.05 price target. To see the full list of analyst forecasts on BetterLife Pharma stock, see the TSE:BETR Stock Forecast page.

BetterLife Pharma Targets Global Partners for BETR-001 at JPM Week Forums

BetterLife Pharma said it will participate in the YAFO Capital Access Asia 2025 Partnering Forum during JPM Week in San Francisco, positioning the company to meet investors, pharmaceutical partners and strategic advisors from North America and Asia as it advances its flagship neurological drug candidate BETR-001. Chief executive Dr. Ahmad Doroudian will also attend a slate of high-profile industry gatherings, including the H7 Life Science Investment Forum, WuXi Global Forum 2026 and the DARPA and Ferocity Capital Biodefence Summit, where he will hold one-on-one meetings to discuss BetterLife’s development strategy for BETR-001, potentially broadening the company’s financing options, partnership prospects and visibility in the global life sciences and biodefence ecosystems.

The most recent analyst rating on (TSE:BETR) stock is a Hold with a C$0.04 price target. To see the full list of analyst forecasts on BetterLife Pharma stock, see the TSE:BETR Stock Forecast page.

BetterLife Pharma Director and Audit Chair Robert Metcalfe Resigns

BetterLife Pharma Inc. has announced the resignation of Robert Metcalfe from its board of directors, where he served for six years and chaired the audit committee, marking a notable change in the company’s governance structure. Chief executive Ahmad Doroudian thanked Metcalfe for his long-standing service and said the company will begin searching for new director candidates as it advances its development plans, a move that could influence oversight and strategic direction as the biotech pursues its neurological and antiviral drug pipeline.

BetterLife Pharma Partners with YAFO Capital for BETR-001 Expansion in Greater China

BetterLife Pharma has engaged Shanghai-based YAFO Capital as its exclusive advisor to seek strategic partnerships for the development of its proprietary BETR-001 in the Greater China regions. This collaboration aims to leverage YAFO’s expertise and network to accelerate the development and strategic partnering opportunities for BETR-001, a non-hallucinogenic treatment for neurological disorders, in Asia.